Lowering blood pressure reduces renal events in type 2 diabetes.
BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recom...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797065235813629952 |
|---|---|
| author | de Galan, B Perkovic, V Ninomiya, T Pillai, A Patel, A Cass, A Neal, B Poulter, N Harrap, S Mogensen, C Cooper, M Marre, M Williams, B Hamet, P Mancia, G Woodward, M Glasziou, P Grobbee, D MacMahon, S Chalmers, J |
| author_facet | de Galan, B Perkovic, V Ninomiya, T Pillai, A Patel, A Cass, A Neal, B Poulter, N Harrap, S Mogensen, C Cooper, M Marre, M Williams, B Hamet, P Mancia, G Woodward, M Glasziou, P Grobbee, D MacMahon, S Chalmers, J |
| author_sort | de Galan, B |
| collection | OXFORD |
| description | BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost. |
| first_indexed | 2024-03-06T21:25:46Z |
| format | Journal article |
| id | oxford-uuid:4308e8f3-e332-4d86-8511-87384d7b2c80 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:25:46Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:4308e8f3-e332-4d86-8511-87384d7b2c802022-03-26T14:53:03ZLowering blood pressure reduces renal events in type 2 diabetes.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4308e8f3-e332-4d86-8511-87384d7b2c80EnglishSymplectic Elements at Oxford2009de Galan, BPerkovic, VNinomiya, TPillai, APatel, ACass, ANeal, BPoulter, NHarrap, SMogensen, CCooper, MMarre, MWilliams, BHamet, PMancia, GWoodward, MGlasziou, PGrobbee, DMacMahon, SChalmers, JBP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost. |
| spellingShingle | de Galan, B Perkovic, V Ninomiya, T Pillai, A Patel, A Cass, A Neal, B Poulter, N Harrap, S Mogensen, C Cooper, M Marre, M Williams, B Hamet, P Mancia, G Woodward, M Glasziou, P Grobbee, D MacMahon, S Chalmers, J Lowering blood pressure reduces renal events in type 2 diabetes. |
| title | Lowering blood pressure reduces renal events in type 2 diabetes. |
| title_full | Lowering blood pressure reduces renal events in type 2 diabetes. |
| title_fullStr | Lowering blood pressure reduces renal events in type 2 diabetes. |
| title_full_unstemmed | Lowering blood pressure reduces renal events in type 2 diabetes. |
| title_short | Lowering blood pressure reduces renal events in type 2 diabetes. |
| title_sort | lowering blood pressure reduces renal events in type 2 diabetes |
| work_keys_str_mv | AT degalanb loweringbloodpressurereducesrenaleventsintype2diabetes AT perkovicv loweringbloodpressurereducesrenaleventsintype2diabetes AT ninomiyat loweringbloodpressurereducesrenaleventsintype2diabetes AT pillaia loweringbloodpressurereducesrenaleventsintype2diabetes AT patela loweringbloodpressurereducesrenaleventsintype2diabetes AT cassa loweringbloodpressurereducesrenaleventsintype2diabetes AT nealb loweringbloodpressurereducesrenaleventsintype2diabetes AT poultern loweringbloodpressurereducesrenaleventsintype2diabetes AT harraps loweringbloodpressurereducesrenaleventsintype2diabetes AT mogensenc loweringbloodpressurereducesrenaleventsintype2diabetes AT cooperm loweringbloodpressurereducesrenaleventsintype2diabetes AT marrem loweringbloodpressurereducesrenaleventsintype2diabetes AT williamsb loweringbloodpressurereducesrenaleventsintype2diabetes AT hametp loweringbloodpressurereducesrenaleventsintype2diabetes AT manciag loweringbloodpressurereducesrenaleventsintype2diabetes AT woodwardm loweringbloodpressurereducesrenaleventsintype2diabetes AT glaszioup loweringbloodpressurereducesrenaleventsintype2diabetes AT grobbeed loweringbloodpressurereducesrenaleventsintype2diabetes AT macmahons loweringbloodpressurereducesrenaleventsintype2diabetes AT chalmersj loweringbloodpressurereducesrenaleventsintype2diabetes |